Premium
Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults – a report on 90 patients
Author(s) -
Damodar Sharat,
Viswabandya Auro,
George Biju,
Mathews Vikram,
Chandy Mammen,
Srivastava Alok
Publication year - 2005
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2005.00545.x
Subject(s) - dapsone , medicine , discontinuation , thrombocytopenic purpura , platelet , purpura (gastropod) , pediatrics , dermatology , surgery , gastroenterology , ecology , biology
Data on 90 patients (55 adults and 35 children) with chronic idiopathic thrombocytopenic purpura (ITP) and a platelet count of <50 × 10 9 /L treated with dapsone at a dose of 1–2 mg/kg/d are presented. A response was observed in 57 (63.3%) patients. The average time for response was 3.5 months (range 1–9) and the average duration of treatment with dapsone was 10.4 months (range 4–14). Overall response rates of 65.7% and 61.8% were observed in children and adults respectively. Side effects requiring discontinuation of therapy were observed in three (2%) patients. These results demonstrate that dapsone is an effective, inexpensive and well‐tolerated treatment for chronic ITP, in both children and adults and could be considered for patients who fail steroid therapy.